Fibromyalgia Syndrome (FMS) is a progressively recognized chronic pain syndrome, which is characterized by it’s constellation of musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back, shoulders, pelvic girdle and hands, but any body part can be implicated. Fibromyalgia patients confront an array of symptoms of varying intensities that are fluxional over time such as; morning stiffness, headaches, irritable bowel syndrome, anxiety, cognitive disorders such as concentration, memory problems, attention deficit disorder, and anxiety. It is estimated that approximately 3-6% of the U.S. population has FM. To read more please click this link: http://css.dewarlorx.com/
Dr. Patty is trying the new medication called Subsys (Member’s Only Section)
I am going to start a new medication called Subsys. As many of you know by the post that I wrote here: http://www.chronicintractablepainandyou.net/new-drug-called-subsys, my insurance did approve the new drug for me. It took a lot of time but it came through. Dennis will be on it as well. The pain doc found a 3rd party payer that will absorb his cost for a year (if the medication works). I will keep you all updated as to how it is working. More information about Subsys, will be in this section.
Predictors of Suicidal Ideation in Chronic Pain Patients DECEMBER 17, 2013 BY BIM
This blog post relates to an article entitled Predictors of Suicidal Ideation in Chronic Pain Patients: An Exploratory Study that Dr. Manon Choinière, Dr. Warren Nielson and I have recently published in The Clinical Journal of Pain . (To read this same blog post in French please click here).
Suicide has always been a very sensitive topic to touch upon, whether it be about “suicidal ideations” (SI), “suicide attempts” (SA) or — god forbid — suicide completion. According to the World Health Organization, death by suicide is one of the leading causes of mortality rate every year (16 per 100, 000 individuals) . The worldwide lifetime prevalence for passive (without plan) and active (with a plan) SI, and SA have been estimated to be 9.2%, 3.1% and 2.7% respectively . In many cases, there is a progression from passive suicidal thoughts to more active thoughts, which may be followed by SAs and in some unfortunate cases, death.
All About Opioids and Opioid-Induced Constipation (OIC)
Treatment options for OIC Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives. How can changing lifestyle factors treat OIC? Changing lifestyle factors is usually the first recommendation that physicians make for the prevention or treatment of constipation. This includes:
Increasing dietary fiber Increasing fluid intake Increasing exercise or physical activity Increasing time and privacy for toileting Changes in lifestyle, however, may not be possible for many patients. In addition, these changes may be ineffective in treating OIC. If there is a concurrent underlying disease or medicine that is causing constipation, the disease may need to be treated separately or another treatment regimen may have to be considered.
Daily Pain Journal
This is another useful practice to get into, and can be therapeutic in dealing with your pain. Describing and recording your pain each day helps you in recognizing any patterns and being aware if anything new is occurring in your body. It will also help you immensely in being able to quickly & accurately describe your pain to your doctor(s).
How does the weather affect your pain or pain syndrome(s)? Please share with us daily so that you can see, read and comment on how the weather affects your pain and those around you! You may be surprised to see that you are not alone in this area also!
A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks.
The FDA has required a REMS for extended-release and long-acting (ER/LA) opioid analgesics.
Under the conditions specified in this REMS, prescribers of ER/LA opioid analgesics are strongly encouraged to do all of the following:
Train (Educate Yourself) – Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) for your discipline